Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium
verfasst von:
Irina Alafuzoff, Dietmar R. Thal, Thomas Arzberger, Nenad Bogdanovic, Safa Al-Sarraj, Istvan Bodi, Susan Boluda, Orso Bugiani, Charles Duyckaerts, Ellen Gelpi, Stephen Gentleman, Giorgio Giaccone, Manuel Graeber, Tibor Hortobagyi, Romana Höftberger, Paul Ince, James W. Ironside, Nikolaos Kavantzas, Andrew King, Penelope Korkolopoulou, Gábor G. Kovács, David Meyronet, Camelia Monoranu, Tatjana Nilsson, Piero Parchi, Efstratios Patsouris, Maria Pikkarainen, Tamas Revesz, Annemieke Rozemuller, Danielle Seilhean, Walter Schulz-Schaeffer, Nathalie Streichenberger, Stephen B. Wharton, Hans Kretzschmar
β-Amyloid (Aβ) related pathology shows a range of lesions which differ both qualitatively and quantitatively. Pathologists, to date, mainly focused on the assessment of both of these aspects but attempts to correlate the findings with clinical phenotypes are not convincing. It has been recently proposed in the same way as ι and α synuclein related lesions, also Aβ related pathology may follow a temporal evolution, i.e. distinct phases, characterized by a step-wise involvement of different brain-regions. Twenty-six independent observers reached an 81% absolute agreement while assessing the phase of Aβ, i.e. phase 1 = deposition of Aβ exclusively in neocortex, phase 2 = additionally in allocortex, phase 3 = additionally in diencephalon, phase 4 = additionally in brainstem, and phase 5 = additionally in cerebellum. These high agreement rates were reached when at least six brain regions were evaluated. Likewise, a high agreement (93%) was reached while assessing the absence/presence of cerebral amyloid angiopathy (CAA) and the type of CAA (74%) while examining the six brain regions. Of note, most of observers failed to detect capillary CAA when it was only mild and focal and thus instead of type 1, type 2 CAA was diagnosed. In conclusion, a reliable assessment of Aβ phase and presence/absence of CAA was achieved by a total of 26 observers who examined a standardized set of blocks taken from only six anatomical regions, applying commercially available reagents and by assessing them as instructed. Thus, one may consider rating of Aβ-phases as a diagnostic tool while analyzing subjects with suspected Alzheimer’s disease (AD). Because most of these blocks are currently routinely sampled by the majority of laboratories, assessment of the Aβ phase in AD is feasible even in large scale retrospective studies.
Introduction
In 1984, Glenner and Wong purified and characterized a novel amyloid protein and in the same year they reported that patients with both Alzheimer’s disease (AD) and Down’s syndrome display this unique cerebrovascular amyloid fibril protein that has been called β-amyloid (Aβ) protein [11, 12]. Later it became evident that the native precursor of this Aβ protein was a membrane associated protein [27]. Subsequently, numerous studies have examined postmortem brains and evaluated the Aβ seen in the parenchyma or vessel walls. Most often postmortem brain material obtained from aged or demented subjects suffering from clinically presumed AD has been investigated by applying immunohistochemical (IHC) methodology.
It has generally been considered sufficient to verify the existence of Aβ-immunoreactive (IR) aggregates in the parenchyma in only one or at the most few brain regions. When evaluating the severity of Aβ deposition in relation to clinical symptoms or the influence of various risk factors on the propensity towards Aβ-IR aggregation investigators have assessed the type of Aβ aggregates, i.e. diffuse versus dense, the number of aggregates or the extent of deposits by means of morphometry [3, 4, 17, 19]. One common finding in aged subjects is the presence of Aβ deposition in vessel walls, i.e. cerebral amyloid angiopathy (CAA) [25] and this is also generally assessed during a neuropathological examination, particularly in subjects with haemorrhages [31]. In 2002, CAA was divided into two types: type 1—CAA is observed in capillaries with or without CAA in arteries and veins and type 2—CAA is detected in arteries and veins [28]. Interestingly, it has been claimed recently that in particular capillary CAA (type 1), is of significance for cognitive impairment probably by causing alterations in the cerebral blood flow as seen in mouse models for CAA and AD [7, 14, 30].
Anzeige
The assessment of Aβ in the parenchyma and in the vessel walls has thus become a part of the routine procedure while handling brains obtained from aged and particularly demented subjects. In 2008, a large inter-laboratory study reported that the agreement was poor while assessing the type (diffuse vs. dense) or the number of IHC detectable Aβ aggregates and the type of CAA, but instead good results could be achieved by applying a dichotomized strategy, i.e. assessment of the presence or absence of Aβ-IR deposits or CAA [6]. The most disturbing factor was that the above results were not significantly altered even when the same antibody provided good IHC staining [6]. The conclusion was that a more reliable and reproducible method is needed for the assessment of the severity of Aβ deposition and the type of CAA in inter-laboratory setting.
In 2002, Thal and colleagues reported that while analyzing 51 postmortem brains, a distinct pattern of involvement of brain regions with Aβ aggregates could be observed [29]. The regional involvement was divided into five phases, i.e. deposition of Aβ detected exclusively in neocortex was called phase 1, if additionally in allocortex it was phase 2, if also in diencephalon and striatum it was phase 3, if also in brainstem it was phase 4 and finally if also in cerebellum it was termed as phase 5. This stepwise involvement was considered to be typical for AD [29].
It was considered that in comparison to the assessment of the type or the density of Aβ-IR lesions, this kind of dichotomized analysis of Aβ-IR in various regions might yield reproducible results even in an inter-laboratory setting [6]. Furthermore, assessment of the regional distribution might be even more significant than previously appreciated. Recent studies have indicated that in subjects with the presenilin-1 mutation the Aβ deposition begins in striatum, i.e. it does not follow the above progression [16, 18]. In other studies, Aβ aggregates have been observed first in deep grey matter structures in dementia with Lewy bodies [2, 13, 24], Parkinson disease with dementia [15] and in subjects with stroke [1]. Thus, the assessment of the distribution of Aβ aggregates in a subject with AD related tauopathy might be more than relevant since any alteration from the expected pattern may reflect a genetic alteration or the existence of a significant concomitant disease process.
The objective of this study was to quantify inter-rater agreement of 26 neuropathologists who were asked to rate Aβ deposits in 34 cases by applying the strategy described by Thal and colleagues [29]. The agreement among observers while assessing CAA and in particular the type of CAA was also examined. A second objective was to identify any pitfalls that might have an impact on the agreement rates.
Anzeige
Materials and methods
The general working schedule is summarized in Fig. 1.
Fig. 1
General structure of the study
×
Sampling of material
Thirty-four cases were included and sampling of blocks was carried out by one neuropathologist (IA). Ten anatomical regions were included in this study: 1—cerebellar hemisphere, 2—midbrain with substantia nigra and central grey, 3—striatum (caudate nucleus and putamen) and insular cortex, 4—basal forebrain (with nucleus basalis of Meynert), amygdala and hypothalamus, 5—cingulated gyrus, 6—hippocampus at the level of lateral geniculate nucleus with CA regions, remnants of ento rhinal cortex and temporo-occipital cortex, 7—occipital cortex, visual cortex including calcarine fissure, 8—temporal cortex, superior and middle temporal gyrus, 9—parietal cortex, Brodmann area 39/40 and 10-frontal cortex, Brodmann area 9. In all of the examined cases Aβ-IR deposits were detected.
A total of five sets of 7 μm-thick sections were produced from all ten brain areas of the 34 cases. The description of these cases is provided in Table 1.
Table 1
Description of the cases included
Case
Gender
Age at death years
Clinical signs of dementia
Primary cause of deatha
Brain weight grams
HP-ι Braak stage (10)
β-amyloid phase (29)
Type of CAAb when present (28)
1
Male
65
No
3
1,290
1
1
0
2
Male
82
No
2
1,595
1
1
0
3
Male
85
No
2
1,605
0
1
0
4
Male
64
No
3
1,510
0
2
0
5
Female
72
Yes
1
1,220
3
3
1
6
Female
88
No
1
1,195
1
3
2
7
Female
92
No
1
1,230
2
3
0
8
Male
70
No
1
1,540
2
3
2
9
Female
80
No
1
1,230
1
3
1
10
Female
90
Yes
2
1,260
3
3
2
11
Male
68
No
1
1,340
2
3
1
12
Male
84
No
2
1,370
1
3
1
13
Female
77
Yes
1
1,240
4
4
2
14
Female
95
Yes
2
1,175
4
4
2
15
Male
79
No
1
1,280
2
4
2
16
Female
76
Yes
2
1,200
3
4
0
17
Male
91
Yes
1
1,115
3
4
1
18
Female
82
Yes
2
1,215
5
4
2
19
Male
81
No
1
1,365
4
4
1
20
Female
84
Yes
1
1,365
4
4
1
21
Female
76
Yes
1
1,275
6
5
1
22
Male
76
Yes
1
1,440
6
5
2
23
Female
64
Yes
1
1,150
3
5
1
24
Female
68
Yes
2
1,400
6
5
1
25
Female
86
Yes
1
1,170
4
5
1
26
Male
73
Yes
2
1,390
3
5
2
27
Male
93
Yes
2
1,380
4
5
1
28
Female
82
Yes
2
1,315
5
5
1
29
Female
82
Yes
1
1,360
5
5
1
30
Female
80
Yes
2
1,250
4
5
1
31
Female
81
Yes
1
1,290
3
5
2
32
Male
72
Yes
1
1,245
3
5
2
33
Female
83
Yes
3
1,285
5
5
2
34
Female
61
No
1
1,425
1
5
1
The phase of β-amyloid deposition and the type of cerebral amyloid angiopathy (CAA) when present as assessed by the reference group
a1—cardiovascular, 2—infections, 3—neoplasia
b0—CAA not present, 1—CAA in capillaries with or without CAA in arteries and or veins, 2—CAA in arteries and veins
Immunohistochemistry
Five sets of the ten sampled sections were manually stained by applying IHC methodology. In brief, after rehydration, one set was pre-treated with 80% formic acid for 6 h and four sets for 1 h. All five sets were subsequently incubated overnight at 4°C with a monoclonal primary antibody directed against Aβ. The first set with an antibody from Dako, clone 6F/3D, dilution 1:100 (Box 1) and four sets with an antibody from Signet, clone 4G8, dilution 1:2000 (Box 2-5). The reaction product was visualized using the Power vision detection system (ImmunoVision Technologies Co., MA, USA) with the use of Biosource Romulin AEC as the chromogen (Biocare medical, Walnut Creek, CA, USA).
The members of the reference group (IA, DRT, TA, ND, HK) jointly re-assessed all cases around a multi-headed microscope. The reference group assigned each case a phase of Aβ deposition and stated whether or not CAA and capillary CAA could be seen (Table 1) [28, 29]. Furthermore, the results obtained with the two different antibodies were compared.
Detailed assessment instructions were written by the reference group. The instructions included a description of the samples, pictures of the pathology that was present and expected to be assessed (Figs. 2, 3, 4), general instructions regarding assessment (Table 2) and tabulated guidelines (Table 3) on how to designate an Aβ phase. Furthermore, each participant was urged to read the original publications on which the assessment procedure was based [28, 29].
Fig. 2
Note the brown cytoplasmic amyloid-β labeling seen when applying the 4G8 antibody in neurons and glial cells (a, b, c, d), ependyma (e), choroid plexus (f) and vessel walls (g). This labeling was not utilized in the classification. Magnification ×400, scale bar 10 μm
Fig. 3
Various amyloid-β aggregates i.e. plaques, seen here in brown colour. Fleecy and diffuse (a–e), subpial band-like (f–h), perivascular lake-like (i) perivascular amyloid-β aggregates that are associated with amyloid angiopathy (j) and diffuse or dense plaques of various sizes and shapes (k–o). Magnification ×400, scale bar 10 μm
Fig. 4
Cerebral amyloid angiopathy (CAA). Mild (a, b) and moderate (c) involvement of leptomeningeal arteries and veins. Primarily arterial and venous (d–h) and primarily capillary (i, j) CAA in the parenchyma (examples of capillary CAA marked with arrows). Note that parenchymal aggregates i.e. plaques are also seen (d–h). Magnification ×400, scale bar 10 μm
Table 2
Instructions for the assessment of β-amyloid (Aβ) immunoreactive (IR) deposits
Section 1. Cerebellum, hemisphere
Section 2. Midbrain at the level of substantia nigra
Section 3. Striatum including insular cortex
Section 4. Hippocampus (posterior) at the level of the lateral geniculate nucleus
Section 5. Basal forebrain including amygdaloid nuclei and nucleus basalis of Meynert
Section 6. Gyrus cinguli at the level of nucleus basalis of Meynert
Section 7. Occipital cortex (visual cortex including the calcarine fissure)
Section 8. Parietal cortex, Brodmann areas 39,40
Section 9. Temporal cortex, superior temporal gyrus and part of middle temporal gyrus
Section 10. Frontal cortex, Brodmann area 9
State for each sample whether or not (yes/no) the region to be assessed (Table 4) is identified
Note that you should only assess the regions requested and disregard lesions in any other region in a section. In midbrain assess substantia nigra and periventricular grey and disregard lesions in any other area e.g., in the superior and/or inferior colliculus. In the basal forebrain block assess amygdaloid nucleus, nucleus basalis of Meynert and hypothalamus, but not globus pallidus etc.
Always ignore cellular Aβ-IR e.g. neuronal or glial cytoplasm and diffuse cytoplasmic labelling of muscle cells (Fig. 2)
State for each assessable and identified region whether or not (yes/no) Aβ-IR aggregates are seen. Aβ aggregates refers to both various parenchymal Aβ aggregates (fleecy, diffuse, lake like, dense etc.) (Fig. 3) and Aβ deposits in blood vessels (cerebral amyloid angiopathy), i.e. arteries, veins and capillaries (Fig. 4)
State for each identifiable regions whether or not (yes/no) Aβ-IR plaques are seen in the neuropil/parenchyma (Fig. 3)
State for the selected region whether or not (yes/no) CAA is seen (Fig. 4)
State for the selected region whether or not (yes/no) capillary CAA is seen (Fig. 4)
Give a Aβ phase following the instructions given in Table 3. Note, while giving the phase assesses only plaques and ignore CAA
Give a type of CAA, i.e. type 2—CAA is seen in arteries and veins, type 1—CAA is seen in capillaries with or without CAA in veins and arteries
Table 3
The five phases of β-amyloid deposition (Thal et al. 2002)
In a typical case detected immunoreactivity should be seen as given in the table. A case that skip’s any of the regions is marked as atypical. The anatomical regions that are particularly important for a given phase are marked in bold
×
×
×
BNE participant efforts
Twenty-six participants assessed each case as instructed, thus each box of five produced sets was assessed by five to six examiners. The results were recorded on sheets (Table 4) which were sent to the coordinating centre. At the coordination centre, all data found in the assessment sheets was collected into one file (MP). These sheets included information on whether or not the participant had identified the required neuroanatomical regions, whether or not Aβ-IR, Aβ-IR plaques, CAA and capillary CAA had been observed and the designated Aβ phase and CAA type of the case. In addition, each participant stated whether or not the distribution of the pathology seemed to progress as expected, i.e. whether it was a typical or an atypical case.
Table 4
Assessment sheet
Consensus meeting and joint assessment
A joint assessment of all IHC labelled sections was carried out around a multi-headed microscope. The diagnostic features of each stage were discussed. While studying the stained sections under the multi-headed microscope, the actual observations were compared with the filed results that had been collected from the original sheets. Inconsistencies in these observations were discussed and pitfalls were identified.
Anzeige
Analysis of the obtained data
At the coordinating centre, the data found in the assessment sheet was re-evaluated. With respect to CAA the results were calculated if only one or some of the sections had been included. Likewise, the influence of a reduction in the number of brain regions provided on the designation of the Aβ phase was analyzed. These calculations were carried out in order to determine the minimum number of neuroanatomical regions required to be assessed in order to achieve the desired result.
Photomicrograph
Digital images were taken using a Leica DM4000 B microscope equipped with a Leica DFC 320 digital camera.
Results
The results when 26 neuropathologists/observers assessed the IHC stained sections of the 34 cases by adhering to the given instructions are summarized in Tables 5 and 6.
Table 5
The β-amyloid phase reported by 26 observers when following the original instructions and while assessing 10 selected brain blocks
Number of cases
β-amyloid phase (Thal et al. 2002) Absolute agreement in percent
Reference phase
0
1
2
3
4
5
All phases
3
1
2
86
4
2
6
84
2
8
3
1
1
81
11
6
8
4
15
74
11
14
5
2
8
90
The absolute agreement between 26 observers and the reference group is given in bold
Table 6
Agreements while assessing cerebral amyloid angiopathy (CAA)
aFrontal and occipital cortices and hippocampus
bCases 5, 12, 17, 19, 20, 23, 24, 25, 30 and 34
cCases 5, 12, 17, 19, 23, 24, 25, 30 and 34
dCases 5, 12, 17, 19, 23, 24, 30
eCases 5, 12, 17,19, 23, 24, 25, 30 and 34
The assigned phase while assessing the sections applying clone 6F3D did not differ from the results obtained with clone 4G8. There was only one case in phase 2 (case 4) and this case was unfortunately not optimal. According to the reference group, case four (Table 1) fulfilled phase 2 criteria in one stained set while applying clone 4G8 (absolute agreement 67%) whereas in the remaining 4 sets, the pathology was seen regionally to such an extent that only phase 1 criteria were fulfilled (absolute agreement 76%). Thus the only phase 2 case has been omitted from Table 5.
Anzeige
Aβ-IR pathology was seen by most raters in all cases. In one case which had been designated as phase 1 by the reference group, two assessors failed to detect any Aβ-IR pathology. The overall agreement while assigning the phase of Aβ deposition in 34 cases was 81% (when case 4 was excluded the value rose to 84%) while assessing all of the ten neuroanatomical regions (Table 5). Most of the cases were considered as being typical, i.e. at least one of the regions required for designation of that phase was affected.
Most of the evaluators participated in the consensus meeting where a joint assessment of the stained sections under a multi-headed microscope and the previous results obtained from the assessors were scrutinized. The group as a whole concluded that all cases were indeed in the phase designated by the reference group.
When assessing the individual results, it was noted that only some of the neuroanatomical regions were required in order to reach a reliable result (Table 6). In all three cases in phase 1, frontal, occipital or temporo-occipital cortices were assessed by most observers as being affected (absolute agreement 84%), in eight cases in phase 3, remnants of ento rhinal cortex (phase 2) and amygdaloid nucleus and nucleus basalis of Meynert (phase 3) were repeatedly affected (absolute agreement 80%).
The agreement while assessing CAA in all ten included sections was as high as 96% (Table 6). Likewise, the agreement was high while assessing leptomeningeal versus parenchymal involvement whereas slightly less harmony was obtained while classifying the type of CAA. There were 16 cases that displayed capillary CAA according to the reference group and this assessment result was verified at the joint assessment session around the multi-headed microscope. In six of the cases (cases 9, 11, 21, 27, 28 and 29), most of the 26 assessors had assigned the case as being of type 2, i.e. no capillary involvement was noted. In all of these cases only few affected capillaries were detected in one or two regions (hippocampus and or occipital cortex). The agreement rates did not change significantly when the number of blocks to be assessed was reduced, though the overall results were significantly different. The overall detection of CAA dropped from 28 to 22 cases, CAA in parenchyma from 24 to 16 cases and the number of cases with type 1 CAA, from 10 to 7 cases (Table 7). The results while assessing CAA in three brain regions, i.e. frontal and occipital cortices and hippocampus [8] or in the six regions selected above were almost the same as those obtained while assessing all ten original blocks.
Table 7
The six blocks required while assessing the phases of β-amyloid deposition
In a typical case, the detected immunoreactivity is seen as described in the table. A case that by passes any of the regions is assigned as being atypical
Anzeige
Discussion
While rating the regional distribution of Aβ-IR, i.e. the phase of Aβ, an 81% agreement was reached when 26 neuropathologists assessed 34 cases all of which displayed Aβ-IR pathology. The agreement increased to 84%, when one case, that in most assessment sets displayed phase 1 and in one set phase 2, was excluded. By following the instructions that were based on the original publication by Thal and colleagues an agreement from 74 up to 90% could be achieved by assessing all ten included brain sections [29]. The lack of a phase 2 case even after a systematic search from a large original sample was unfortunate however; this might indicate that this phase is quite unusual or perhaps even virtually non-existent. Only a systematic assessment of forthcoming cases will resolve this issue.
Interestingly, similar agreement rates and assessment results were obtained when the number of blocks was reduced to six. It is noteworthy that these blocks are the same that are commonly sampled while working with brain specimens that have to be evaluated either due to the high age of the deceased or due to an age related neurodegenerative disorder. The hippocampal section and occipital cortex are assessed when dealing with AD-related tauopathy, basal forebrain section is evaluated when dealing with tauopathies and especially when one needs to deal with synucleinopathy, the midbrain section is examined when dealing with synucleinopathy, the section obtained from frontal cortex is assessed when dealing with TAR DNA binding protein (TDP-43) related pathology and finally cerebellum is evaluated when there is a suspicion of spinocerebellar ataxias [5, 9, 10, 20‐23, 26]. Thus, these six brain sections are probably sampled in all laboratories during a routine neuropathological evaluation and consequently the proposed assessment of Aβ phase is quite feasible.
The high agreement here was also related to the fact that the assessors only had to evaluate the absence or presence of Aβ-IR pathology and thus the results were not influenced by the previously reported variability in the assessment of the extent of the pathology [6].
The agreement rates with respect to CAA were also high. Almost all, 96% of observers noted vascular involvement in the 28 cases in the same way as originally characterized by the reference group and confirmed in the joint assessment carried out around a multi-headed microscope. This result was not altered when only six blocks were selected.
The agreement was close to 80% in the classification of the type of CAA, i.e. 76% of assessors had seen capillary involvement in ten of the included cases. It is noteworthy that in six cases, most of the observers had failed to detect capillary CAA and only arterial and/or venous involvement was registered. In all of these cases, only a few capillaries in one or two regions were involved. This result emphasises that mild capillary involvement even after assessing numerous brain regions might easily be overlooked. The reliable assessment of capillary CAA is of particular importance in subjects with dementia lacking any other pathological alterations that can be considered as causative with respect to the clinical syndrome.
Here we noted that when only one cortical region was assessed, the agreement rates dropped marginally but more importantly the detection of CAA and particularly capillary CAA did change significantly, declining from 10 to 7 cases. Capillary CAA in one brain region has been assessed by Attems and Jellinger in 2004 [7] and by Jeynes and Provias in 2006 [14]. Both groups reported a significant correlation between capillary CAA and AD lesions. Based on our results, the strong association between AD lesions and capillary CAA should probably be re-evaluated including a larger number of regions. In 2008, Attems and colleagues reported a low prevalence of intracerebral haemorrhage in sporadic CAA when they assessed CAA in frontal and occipital cortices and also hippocampus [8]. While applying their strategy, including these three brain areas in the assessment, all 28 subjects with CAA were identified and in nine out of ten cases type 1 CAA was detected by most of the observers. Thus, by assessing these three blocks essentially equivalent results can be achieved as by assessing all ten blocks.
In epidemiological studies, one may need to assess huge sample sizes, e.g. thousands of cases. This is also the case when searching for risk genes. In both situations, material obtained from several laboratories will need to be combined. Furthermore, not only numerous samples need to be evaluated but they also have to be reliably and reproducibly characterized. Here we report that a high agreement can be achieved while assessing the regional distribution of Aβ-IR pathology and the absence/presence of CAA. With respect of capillary CAA, it should be borne in mind that a mild focal capillary CAA might be overlooked whereas in those cases where there is moderate involvement, the agreement regarding the detection of type 1 CAA is rather high. This reliable assessment of Aβ phase, presence/absence of CAA and type 1 CAA was reached by staining a standardized set of blocks taken from six neuroanatomical regions and by applying a commercially available reagent. The investigators were requested to follow written instructions. It is noteworthy that most of the blocks included here are currently routinely sampled by the majority of laboratories and thus even large scale retrospective studies could be organized. Therefore, determination of the phase of Aβ-deposition may represent a reliable and reproducible tool to describe and quantify AD related Aβ pathology in post-mortem brain specimens.
Acknowledgments
We thank Mrs Tarja Kauppinen, Mrs Merja Fali, Mr Heikki Luukkonen and Mr Hannu Tiainen for technical assistance. This study was supported by European Union grant FP6: BNEII No LSHM-CT-2004-503039. This article reflects only the authors’ views and the European Community is not liable for any use that may be made of the information contained therein. The study has been approved by the Ethics Committee of Kuopio University Hospital.
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (
https://creativecommons.org/licenses/by-nc/2.0
), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium
verfasst von
Irina Alafuzoff Dietmar R. Thal Thomas Arzberger Nenad Bogdanovic Safa Al-Sarraj Istvan Bodi Susan Boluda Orso Bugiani Charles Duyckaerts Ellen Gelpi Stephen Gentleman Giorgio Giaccone Manuel Graeber Tibor Hortobagyi Romana Höftberger Paul Ince James W. Ironside Nikolaos Kavantzas Andrew King Penelope Korkolopoulou Gábor G. Kovács David Meyronet Camelia Monoranu Tatjana Nilsson Piero Parchi Efstratios Patsouris Maria Pikkarainen Tamas Revesz Annemieke Rozemuller Danielle Seilhean Walter Schulz-Schaeffer Nathalie Streichenberger Stephen B. Wharton Hans Kretzschmar
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
